Carrie Heuck, NP
Acute Care · Indianapolis, INNPI 1457466757
Payments from drug & device makers
Across 72 payments — averaging $16.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$248
- Novo Nordisk$201
- Insulet Corporation$127
- Xeris Pharmaceuticals, Inc.$123
- Bayer$71
- Amneal Pharmaceuticals LLC$49
- plus $398 from 15 others
What the payments were for
- Food & beverage$1,217100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 15 | $248 |
| Novo Nordisk | 17 | $201 |
| Insulet Corporation | 4 | $127 |
| Xeris Pharmaceuticals, Inc. | 6 | $123 |
| Bayer | 5 | $71 |
| Amneal Pharmaceuticals LLC | 3 | $49 |
| Boehringer Ingelheim | 3 | $48 |
| Corcept Therapeutics | 2 | $38 |
| Cequr Corporation | 2 | $37 |
| Dexcom, Inc. | 2 | $34 |
| Tandem Diabetes Care, Inc. | 1 | $32 |
| Amgen | 2 | $32 |
| AstraZeneca | 2 | $29 |
| Averitas Pharma Inc. | 1 | $23 |
| Abbott | 1 | $21 |
| Chiesi USA, Inc. | 1 | $20 |
| Exact Sciences | 1 | $19 |
| Medtronic | 1 | $17 |
| Antares Pharma, Inc. | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
How this compares
$1,217 in reported general payments places this provider in the 70th percentile of 240 acute care providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 240 | $262,070 |
| OzempicSemaglutide | 159 | $195,256 |
| FarxigaDapagliflozin Propanediol | 179 | $161,163 |
| JardianceEmpagliflozin | 143 | $142,505 |
| TrulicityDulaglutide | 61 | $82,547 |
| RybelsusSemaglutide | 63 | $82,150 |
| JanuviaSitagliptin Phosphate | 86 | $70,007 |
| TradjentaLinagliptin | 89 | $56,924 |
| KerendiaFinerenone | 54 | $49,511 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 55 | $49,104 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 27 | $37,709 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 28 | $26,276 |
| JanumetSitagliptin Phos/Metformin Hcl | 35 | $26,251 |
| Repatha SureclickEvolocumab | 32 | $21,757 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 40 | $21,649 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $248 | $353,748364 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $201 | $283,129250 claims |
| Boehringer IngelheimJardiance, Tradjenta | $48 | $199,428232 claims |
| AstraZenecaFarxiga | $29 | $161,163179 claims |
| BayerKerendia | $71 | $49,51154 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $49 | $3,299132 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 240 acute care providers in Indiana.
Other acute care in Indianapolis
- Lauren ArmingtonIndianapolis$7K
- Ashley HillIndianapolis$7K
- Rebecca DavidhizarIndianapolis$3K
- Jennifer JimenezIndianapolis$3K
- Jennifer DimitroffIndianapolis$3K
- Lisa SimsIndianapolis$3K
- Kylie BeutlerIndianapolis$2K
- Alexis SmithIndianapolis$2K
- Katelyn PorterIndianapolis$2K
- Rebecca CobbIndianapolis$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.